Liver Diseases  >>  beclabuvir (BMS-791325)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beclabuvir (BMS-791325) / BMS
NCT01979939 / 2013-002468-20: UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Checkmark AASLD 2014: UNITY 1
Oct 2014 - Oct 2014: AASLD 2014: UNITY 1
Checkmark Presentation of UNITY-1 data for HCV at AASLD
Oct 2014 - Oct 2014: Presentation of UNITY-1 data for HCV at AASLD
Checkmark Initiation of daclatasvir + asunaprevir + NS5B non-nuc triple combo trial for GT1 hep C infection
More
Completed
3
416
US, Canada, Europe, RoW
DCV/ASV/BMS-791325
Bristol-Myers Squibb
Hepatitis C
08/14
11/14
NCT02123654: UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Completed
3
297
Japan
Daclatasvir, Asunaprevir, DCV 3DAA, Daclatasvir 30 mg /Asunaprevir 200 mg /BMS-791325 75 mg fixed dose combination, Placebo for DCV 3DAA, Placebo for Daclatasvir, Placebo for Asunaprevir
Bristol-Myers Squibb
Hepatitis C Virus Infection
01/15
08/15

Download Options